# Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients

> **NCT07690943** · NA · COMPLETED · sponsor: **LucasBio** · enrollment: 13 (actual)

## Conditions studied

- COVID-19
- COVID-19 (SARS-CoV-2 Infection)

## Interventions

- **BIOLOGICAL:** LB-DTK-COV19

## Key facts

- **NCT ID:** NCT07690943
- **Lead sponsor:** LucasBio
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-08
- **Primary completion:** 2024-05-31
- **Final completion:** 2025-01-22
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690943, "Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*